Hygeia Ventures invests in early-stage European HealthTech companies that have achieved technical and regulatory de-risking through public or institutional validation — entering after scientific proof, before the scale-up capital arrives.
EU-funded research is cited twice as often as the global average, yet European life sciences VC captures just 7% of global market share against 63% for the US. The result is a pipeline of technically validated, publicly de-risked ventures starved of the capital that would take them to scale.
Hygeia Ventures was built to close that gap — entering after scientific validation, after grant-based non-dilutive funding, and before institutional scale capital.
Pre-vetted pipeline from EU funding instruments, EIT KICs, tech-transfer offices and innovation hubs across eight countries.
Combined 30+ years of operational experience across life sciences, Health AI, digital health and regulatory pathways.
Active relationships spanning Scandinavia, DACH and Southern Europe — with a pipeline of 100+ companies tracked.
Early-stage enablers take science out of the lab. Growth funds take companies to global scale. Hygeia Ventures bridges the gap between them — partnering with both, taking de-risked innovation from validation to commercial inflection and major exits.
Data room available under NDA for professional investors.